Aura Biosciences (AURA) Invested Capital (2020 - 2026)

Aura Biosciences has reported Invested Capital for 7 years, with the latest figure at $107.2 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 16.19% year-over-year to $107.2 million; the trailing twelve-month figure through Mar 2026 stood at $107.2 million (down 16.19% YoY), and the FY2025 full-year result was $136.9 million, down 9.91% from the prior year.
• Invested Capital for Q1 2026 stood at $107.2 million, down from $136.9 million in the prior quarter.
• The five-year high for Invested Capital was $225.8 million in Q4 2023, with the low at $107.2 million in Q1 2026.
• Historically, Invested Capital has averaged $160.9 million across 5 years, with a median of $156.7 million in 2025.
• Annual changes were most pronounced in 2022 — Invested Capital soared 223.55% — and 2025, when it slumped 38.71%.
• Aura Biosciences' Invested Capital stood at $195.6 million in 2022, then increased by 15.47% to $225.8 million in 2023, then plunged by 32.71% to $152.0 million in 2024, then fell by 9.91% to $136.9 million in 2025, then slipped by 21.67% to $107.2 million in 2026.
• The last three Invested Capital figures came in at $107.2 million (Q1 2026), $136.9 million (Q4 2025), and $156.7 million (Q3 2025), per Business Quant data.